Pharmaceutical News and Articles

Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and al

Shortened BDLC Regimen Not Noninferior for Drug-Resistant TB

For preextensively drug resistant tuberculosis (TB), a shortened bedaquiline, delamanid, linezolid, and clofazimine (BDLC) regimen is not noninferior to longer

Myocardial Fibrosis Linked to Ventricular Arrhythmia in Male Endurance Athletes

Myocardial fibrosis is independently associated with the onset of ventricular arrhythmia in male veteran endurance athletes, according to a study published onli

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

For Some, Gluten Intolerance Is Psychological, Study Says

TUESDAY, July 22, 2025 Gluten intolerance might be all in the minds of some people with irritable bowel syndrome (IBS), results from a small-scale experiment in

Four-Day Work Week Benefits Workers, Employers, Study Says

TUESDAY, July 22, 2205 A four-day work week can lead to happier and more productive, dedicated employees, a new global study found.Workers at companies that ins

Dogs Can Sniff Out Parkinson's Disease, Study Shows

TUESDAY, July 22, 2025 Dogs noses are sensitive enough to track down fleeing convicts, locate human remains in hidden burial sites and detect illicit drug stash

Few Schools Screen Students For Depression, Anxiety

TUESDAY, July 22, 2025 Fewer than one-third of American public schools are screening students for psychological problems, years after the U.S. Surgeon General d

Americans Braced For Loss Of Gender-Affirming Care

TUESDAY, July 22, 2025 Just about all transgender Americans believe they ll lose their access to gender-affirming health care during President Donald Trump s cu

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease

Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n 1,301) and the Phase III